ArticleFrontline gastroenterology2019
A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health.
Article in Frontline gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Pooled it
- Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review.Advances in therapy · 2020Pooled it
- Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.Clinical and molecular hepatology · 2026Review
- Review
- Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost analysis from a tertiary-care, multidisciplinary MAFLD clinic.Internal medicine journal · 2026Article
- Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan.Journal of gastroenterology · 2026Review
- Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions.Diabetes, obesity & metabolism · 2026Review
- Bridging the Knowledge Gap: A National Survey on MASLD Awareness and Management Barriers in the Saudi Population.Healthcare (Basel, Switzerland) · 2025Article
- A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.Diabetes, obesity & metabolism · 2025Review
- Mapping Metabolic Dysfunction-associated Steatotic Liver Disease Models of Care across 17 Middle East and North Africa Countries: Insights into Guidelines, Infrastructure, and Referral Systems.Journal of clinical and translational hepatology · 2025Article
- Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.BMC gastroenterology · 2025Article
- A Survey Assessing Nonalcoholic Fatty Liver Disease Knowledge Among Hepatologists and Non-Hepatologists in China.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Quantitative Imaging Reveals Steatosis and Fibroinflammation in Multiple Organs in People With Type 2 Diabetes: A Real-World Study.Diabetes · 2024Article
- AMPED study: Protocol for a randomized controlled trial of different doses of aerobic exercise training.Hepatology communications · 2024Article
- Serum biomarkers for liver fibrosis assessment.Advances in laboratory medicine · 2024Review
- Article
- Updates in nonalcoholic fatty liver disease.Clinical liver disease · 2023Article
- Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention.BMJ (Clinical research ed.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a globally prevalent health problem, associated in its more severe forms with increased liver-related and cardiovascular-related morbidity and mortality. We established a multidisciplinary metabolic hepatology clinic in 2014 and have analysed the clinical data to evaluate the effectiveness of this service. Patients with NAFLD (n=165) who had attended two or more appointments were included. Prespecified clinical data were collected prospectively at clinic appointments and analysed retrospectively. Interventions offered included lifestyle advice, signposting to weight loss services and pharmacological treatment of diabetes and cardiovascular risk factors. Median follow-up was 13 months (range: 2-34). 59% (n=97) of patients had type 2 diabetes mellitus (T2DM). 53% (n=87) underwent liver biopsy of whom 18% (n=16) had cirrhosis. Median alanine aminotransferase (ALT) reduced by 11 IU/L (p<0.0001), median weight reduced by 3.3 kg (p=0.0005). There were significant reductions in HbA1c, total cholesterol and liver stiffness. Specifically, in patients with T2DM, HbA1c decreased by 4 mmol/mol (p=0.01) with significant reductions in ALT, weight and total cholesterol. Relative cardiovascular risk assessed by the QRISK3 score reduced in the whole cohort and in those with T2DM. Health economic modelling suggested the clinic intervention among those patients with poorly controlled T2DM was cost-effective. In conclusion, a multidisciplinary approach to the management of patients with NAFLD in this observational cohort study was associated with improvements in liver-related and cardio-metabolic related health parameters and with evidence of cost-effectiveness in patients with poorly controlled T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.